Actively Recruiting
PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic Value
Led by University Hospital, Strasbourg, France · Updated on 2026-01-02
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying invasive pulmonary aspergillosis, a serious fungal infection, by evaluating the prognostic value of Aspergillus fumigatus PCR levels in blood and bronchoalveolar lavage fluid. The focus is on how variations in PCR levels during antifungal treatment might relate to treatment effectiveness and disease progression, as current data on this topic are limited. This observational study involves patients diagnosed with invasive aspergillosis who have a positive Aspergillus fumigatus PCR test. The PCR tests are used to monitor fungal load and disease stage but no specific treatments or interventions are assigned by the study since it observes existing clinical care. Participants will be followed to assess outcomes such as death rate at day 30 after starting antifungal treatment, particularly in those with positive follow-up PCR tests. The study collects PCR results and clinical data over time to understand correlations with treatment outcomes. Participation duration and exact monitoring schedules vary based on patient care but include regular PCR assessments and clinical follow-up.
CONDITIONS
Brief Title
PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic Value
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years or older
- Positive Aspergillus fumigatus PCR on serum or bronchoalveolar lavage fluid at diagnosis, performed at the Strasbourg University Hospital between January 1, 2017, and December 31, 2024
You will not qualify if you...
- No subsequent Aspergillus fumigatus PCR more than 24 hours after the initial test
- No diagnosis of probable or proven invasive aspergillosis according to EORTC/MSGERC 2020 criteria
- Started effective antifungal treatment against Aspergillus before the first PCR test
- Death within 72 hours after starting antifungal treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 30 days after antifungal treatment
Participants who have a positive Aspergillus fumigatus PCR test are observed over time to monitor disease progression and outcomes.
Trial Site Locations
Total: 1 location
1
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, France, 67091
Actively Recruiting
Research Team
B
baptiste Hoellinger, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here